Macquarie Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

Macquarie Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-153,941	Closed	-$9.21M	–	2043
2019 Q4	$9.21M	Hold	153,941	–	–	0.01%	664
2019 Q3	$4.32M	Hold	153,941	–	–	0.01%	801
2019 Q2	$5.83M	Sell	153,941 -26,059	-14%	-$1M	0.01%	735
2019 Q1	$7.02M	Buy	180,000 +49,900	+38%	+$1.43M	0.01%	699
2018 Q4	$2.77M	Hold	130,100	–	–	0.01%	886
2018 Q3	$5.15M	Buy	130,100 +23,500	+22%	+$876K	0.01%	779
2018 Q2	$4.07M	Buy	+106,600	New	+$3.95M	0.01%	825

Macquarie Group's BOLD Position: Q1 2020 in Review

Macquarie Group sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 153,941 shares — an estimated $9.21M sold.

Macquarie Group first reported a position in BOLD in Q2 2018 and held it in 7 quarters. The position peaked at $9.21M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Macquarie Group reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Macquarie Group sold 153,941 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $9.21M.
Macquarie Group first reported a position in Audentes Therapeutics, Inc in Q2 2018 and held it in 7 quarters.
Macquarie Group's Audentes Therapeutics, Inc position peaked at $9.21M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Macquarie Group's 13F filing for Q1 2020, filed 15 May 2020.